Read details of what our officials, members and supporters did as well our finances between April 2025 and March 2026 in the latest Aniridia Network Annual Report

The Annual General Meeting (AGM) of Aniridia Network, a charitable incorporated organisation, will be held online on 28/11/2026.

Nine patients were treated with a transplant of a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells

During our online meetup earlier this year to mark Aniridia Day and Father’s Day, we were given a preview of an important new research project. Harriet, an MSc Genetic Counselling student fro…

During our online meetup earlier this year to mark Aniridia Day and Father's Day, we were given a preview of an important new research project. Harriet, an MSc Genetic Counselling student from Cardiff University, is preparing to conduct a study with Aniridia Network, which will ask the question: "What is the impact on family members of the diagnosis of aniridia in a child, and what would help?

Stem cell scaffold RAFT-OS restored vision in 9 adults with aniridia-related keratopathy, gaining nearly five chart lines in a first-in-human trial.

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy.

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy.

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy.

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy.

The Drosophila gene eyeless (ey) encodes a transcription factor with both a paired domain and a homeodomain. It is homologous to the mouse Small eye (Pax-6) gene and to the Aniridia gene in humans. Th...

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy.

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy.

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy.

A dual stem cell scaffold improved vision and eye surface scores in a small first-in-human trial for aniridia-related keratopathy. For people with ARK (aniridia-related keratopathy), progressive damage to the eye’s surface can gradually cloud the cornea and severely reduce vision. In a first-in-human clinical trial at Moorfields Eye Hospital and University College London (UCL), a [...]

A new stem cell treatment for ARK (aniridia-related keratopathy) improved patients' vision in a first-in-human clinical trial for this previously untreatable rare genetic eye condition at Moorfields E...

As soon as her daughter was born, Stephanie DeRosa-Marrazzo knew the child had inherited her husband’s rare eye disease. Instead of a blue or brown iris, Pandorraa’s eyes only had pools of black pupil—the signature of a condition known as aniridia that causes cataracts, glaucoma, and other forms of vision loss. When Stephanie’s second child was born six years later, the couple held their breath. Aayden, however, was born with seemingly healthy vision. “The eye doctor told us he looked fine,” Stephanie says. The only difference doctors could find was a small red mark outside a brilliantly blue iris. Which is why Stephanie was so shocked when she learned years later that her son, now 11, likely carried the same mutation of the PAX6 gene on chromosome 11 that had stolen the vision of his sister and father. (They were blinded in accidents. Now, they can see again.) Not all that long ago, scientists like Eric Pierce and Elizabeth Rossin would have told you that disease-causing genetic variants were extremely rare, and that anyone carrying one would almost certainly develop the associated disease—whether it was cystic fibrosis, spinal muscular atrophy, amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease),...

A new stem cell treatment for ARK (aniridia-related keratopathy) improved patients' vision in a first-in-human clinical trial for this previously untreatable rare genetic eye condition at Moorfields E...

A first-in-human clinical trial reported improved vision after stem cell treatment in patients with aniridia-related keratopathy (ARK), a rare genetic eye condition. ...

A new stem cell treatment for ARK (aniridia-related keratopathy) improved patients' vision in a first-in-human clinical trial for this previously untreatable rare genetic eye condition at Moorfields E...

A new stem cell treatment for ARK (aniridia-related keratopathy) improved patients' vision in a first-in-human clinical trial for this previously untreatable rare genetic eye condition at Moorfields Eye Hospital and University College London (UCL), published in JAMA Ophthalmology.